Seoulin Bioscience Co.Ltd Asset Resilience Ratio
Seoulin Bioscience Co.Ltd asset resilience ratio. Seoulin Bioscience Co.Ltd (038070) has an Asset Resilience Ratio of 20.42% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 038070 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Seoulin Bioscience Co.Ltd (2013–2025)
Asset resilience ratio of Seoulin Bioscience Co.Ltd from 2013 to 2025. This chart shows how Seoulin Bioscience Co.Ltd's Asset Resilience Ratio has changed over time. Read 038070 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Seoulin Bioscience Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Seoulin Bioscience Co.Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩24.26 Billion | 20.42% |
| Total Liquid Assets | ₩24.26 Billion | 20.42% |
Asset Resilience Insights
- Good Liquidity Position: Seoulin Bioscience Co.Ltd maintains a healthy 20.42% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Seoulin Bioscience Co.Ltd Industry Peers by Asset Resilience Ratio
Compare Seoulin Bioscience Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Seoulin Bioscience Co.Ltd Asset Resilience Ratio by Year (2013–2025)
Seoulin Bioscience Co.Ltd asset resilience ratio by year from 2013 to 2025. The table below shows the annual Asset Resilience Ratio data for Seoulin Bioscience Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 20.42% | ₩24.26 Billion ≈ $16.44 Million |
₩118.80 Billion ≈ $80.51 Million |
-1.59pp |
| 2024-12-31 | 22.02% | ₩22.36 Billion ≈ $15.15 Million |
₩101.52 Billion ≈ $68.80 Million |
-6.79pp |
| 2023-12-31 | 28.81% | ₩32.88 Billion ≈ $22.28 Million |
₩114.10 Billion ≈ $77.32 Million |
-10.33pp |
| 2022-12-31 | 39.14% | ₩52.79 Billion ≈ $35.78 Million |
₩134.87 Billion ≈ $91.40 Million |
-14.52pp |
| 2021-12-31 | 53.66% | ₩73.28 Billion ≈ $49.66 Million |
₩136.57 Billion ≈ $92.55 Million |
+29.56pp |
| 2020-12-31 | 24.10% | ₩18.86 Billion ≈ $12.78 Million |
₩78.25 Billion ≈ $53.03 Million |
-3.21pp |
| 2019-12-31 | 27.30% | ₩22.04 Billion ≈ $14.93 Million |
₩80.71 Billion ≈ $54.69 Million |
+13.63pp |
| 2018-12-31 | 13.68% | ₩9.73 Billion ≈ $6.59 Million |
₩71.11 Billion ≈ $48.19 Million |
-1.55pp |
| 2017-12-31 | 15.23% | ₩10.82 Billion ≈ $7.33 Million |
₩71.04 Billion ≈ $48.14 Million |
-9.54pp |
| 2016-12-31 | 24.77% | ₩16.46 Billion ≈ $11.16 Million |
₩66.47 Billion ≈ $45.05 Million |
-4.59pp |
| 2015-12-31 | 29.36% | ₩19.41 Billion ≈ $13.15 Million |
₩66.10 Billion ≈ $44.80 Million |
-2.45pp |
| 2014-12-31 | 31.81% | ₩19.32 Billion ≈ $13.09 Million |
₩60.72 Billion ≈ $41.15 Million |
-1.62pp |
| 2013-12-31 | 33.44% | ₩20.19 Billion ≈ $13.68 Million |
₩60.39 Billion ≈ $40.92 Million |
-- |
About Seoulin Bioscience Co.Ltd
Seoulin Bioscience Co.,Ltd., a bio healthcare company, provides solutions in life sciences and healthcare primarily in South Korea. The company offers solutions for bio research and production; ecoTree, a SLB-120 instrument which produces slightly acidic electrolyzed water for used in food industry, living, and laboratory; plasma-based medical esthetics; miQ for the diagnosis of dementia; and fun… Read more